Zymeworks Inc. is a privately held biotechnology company committed to developing best-in-class protein therapeutics for the treatment of cancer.
Advaxis ADXS-PSA Construct Causes Significant Tumor Regression in Preclinical Prostate Cancer Study
According to the American Cancer Society, prostate cancer is the most common type of cancer found in American men, other than skin cancer.
OncoSec to Present at Upcoming Investor and Scientific Conferences
OncoSec Medical is a biopharmaceutical company developing advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease.
Industry Veteran Named CEO of Vigilant Biosciences
New “rinse and spit” screen for oral cancer could reduce disfigurement and save lives. Vigilant Biosciences, Inc., recently announced the appointment of David Barshis as Chief Executive Officer.
Immunotherapy Trains the Immune System to Attack Cancer Cells
Immunotherapy is the new black when it comes to treating Cancer, raising hope in conquering this age old illness.
Four Cancer Therapies to Watch
On June 1, more than 25,000 cancer specialists will come together at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago. With ASCO hours away, we look at some small biotech companies making headway in cancer treatment.
Biovest Seeking Marketing Approval in the EU for BiovaxID® Personalized Lymphoma Cancer Vaccine
Biovest has developed a patient-specific, cancer vaccine, BiovaxID®, with three clinical trials completed.
OneMedRadio: NanoViricides CEO Discusses U.S. Patent
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for antiviral therapy.
